Member Info for BuenaVista

I think at least some of it was to do with Sheppy admitting he slept in his dad's porch. All those posts got pulled, not the complete thread for a change.

Don't be fooled by that snake Tom_Winnifilth.

An ode or lament to bad teeth:

In a market where mischief casts its darkened shade, - Lived a boy named Truant, cruel and unafraid. - His teeth, a grim reminder of his twisted ways, - In a world of deceit, he sought to amaze.

With a wicked smirk and a sinister scheme, - He spun a web of lies, a dreadful dream. - "Buy shorts," he hissed, with venom in his voice, - "Your riches will multiply; it's the only choice."

The traders, deceived, fell into his snare, - Buying shorts with hopes, unwise to the 'mare. - As the market tumbled, their fortunes were aglow, - Truant's twisted joy began clearly to show.

But Truant was no fool, his intentions vile, - As the market plummeted, he hid a wily smile. - He went long on stocks, when they were dirt cheap, - As their price rebounded, he'd sow what he'd reap.

With rotten teeth and a heart filled with malice, - Truant played the market like a cruel chalice. - As stocks soared high and riches heaped around, - He reveled in their losses, laughter unbound.

Yet in this tale of deceit and wicked vice, - A lesson emerges, both cold as ice. - For Truant's treachery may have caused pain, - But karma has a way of evening the gain.

In the end, remember, it's not all about gold, - Honesty and kindness are more precious, we're told. - For in life's unpredictable, tumultuous sweep, - Sometimes, it's the wicked who sow what they'll reap.

Alan with his finger on the pulse.

And an epic concerning the valiant Icecool...

In the realm of stocks, where fortunes sway, - Fair Icecool rose to face evil Sheppy one day. - With heart as noble as a knight of old, - Icecool embarked on a quest brave and bold.

Sheppy, the deramper with schemes so vile, - Sought to tarnish Avacta's golden smile. - With dark intentions and venomous glee, - He aimed to drag the company down to the sea.

Icecool, with wisdom and knowledge profound, - In the battlefield of stocks, stood his ground. - With truth and honesty as his shining shield, - He rode into the chaos of the market's field.

Their epic battle, a clash of light and dark, - Would determine Avacta's fate, a crucial mark. - Sheppy's deceitful words, like arrows they flew, - While Icecool's resolve and integrity grew.

He countered Sheppy's falsehoods with facts so clear, - Dispelling the shadows, making truth reappear. - The market watched in awe and admiration, - As Icecool's steadfastness sparked a transformation.

With every blow from Sheppy, Icecool stood tall, - Defending Avacta, he'd never let it fall. - Through the storms of deception and manipulative play, - Icecool's courage and virtue would win the day.

In the end, the evil Sheppy was defeated, - His wicked plans, by Icecool, were unseated. - Avacta's value soared to new heights, - As truth and fairness vanquished the darkest nights.

In the world of stocks, where battles are fought, - Icecool's victory was a lesson well-taught. - That integrity and honesty, against all odds, - Can triumph over darkness, like the brightest of gods.

So, here's to Icecool, the hero so fair, - Whose battle with Sheppy was beyond compare. - In the epic saga of the market's strife, - He proved that goodness is the key to life.

ChatGPT is great fun, always something different.

In the world of stocks, there lived a dark shade, - A deramper named Sheppy, in shadows he played. - With schemes and intentions both sinister and cruel, - He aimed to disrupt Avacta, a company's soul.

But Sheppy, though evil, was not quite astute, - His plans often crumbled, his strategies mute. - Incompetence masked by his malevolent guise, - He stumbled through chaos with wide-open eyes.

He'd spread his false rumors with clumsy intent, - Yet somehow, the market was left largely unpent. - His plots lacked precision, his execution flawed, - Avacta stood firm, its foundation unclawed.

With a devilish grin and a lackluster plan, - He tried to unravel the market, an evil man. - But his schemes fell apart, like a house made of cards, - Leaving investors to wonder why it was so hard.

In the heart of darkness, a glimmer did gleam, - A deramper named Sheppy, lost in his own dream. - Ineptitude masked by his wicked charade, - A villain so bumbling, in the stock market's arcade.

So, here's to Sheppy, the evil but inept, - Whose efforts to harm often left investors prepped. - In the world of stocks, where cunning's the norm, - Sometimes, incompetence can soften the storm.

Sheppy, 7 Sep 2023 16:19

"CJ62 I hope so too as I have a small holding in this biotech however I’m not taken in by all this blind hype and unhinged belief that this share will change everyone’s life. It could just as easily go the other way as most what appear to be promising biotechs usually do,"

You have a small holding 🤥😂😂😂

**** yes, you're right Tim: the FDA, the MHRA and HCI as well. All helpless, naive suckers for Alan's silvery tongue and magic crayons. He's going to need to sell another huge tranche to pay for all those shumpers.

you're absolutely right of course sheppy. and it's not just alan who's been lying to us and the market throughout all this time, it's all of the avacta bod and senior management and, worst of all, all those clinicians carrying out the trial who are just throwing their hard earned reputations and livelihoods away on the promise of a christmas shumper. you're a very astute dude sheppy. now that you've made me stop and think i can see it all now. you are a complete ******.

🐑🩳🔥😂

They are not obliged to announce the appointment.

Nice change from "can be used to modify" to "modifies"!

Really good news, and only a few away.

Might this shift the share price? Probably not!

Ah, I see what you mean. I had taken it to be completion of data analysis of C1-C6 plus preparation of the data presentation (and reviewing and double checking!) and as much of C7 (initial data at least) that can be squeezed in before year end.

C6 has completed already. We are now on C7.

Only 2 cycles are required for each cohort. The time it takes is equivalent to 3 cycles for the first patient and 2 for the others.

Patients may continue on treatment after the cohort has completed, providing Phase 1b-type (extended use) data.

Alan also described it as a (proposed) 'registrational Phase 2' study, which is the same thing but a clearer descriptor.

However, 'pivotal' is the generally used term.

Timster, the parallel dose escalation study will be conducted solely in the US with patients with one of two (I think he said two) STS sub-types. These will hopefully be a highly susceptible sub-type and a much less susceptible sub-type so that if efficacy is shown against the latter, then AVA6000 could be registered for all the sub-types in between. Or they will choose two susceptible sub-types!

They didn't RNS when the MHRA gave permission to dose above 200mg/m² but did when C5 started. Who knows whether they will do that for Phase 1aMk2 or whether they will go for full promotion (boosting is such a crude word) and RNS the permission to proceed, followed shortly after by the announcement of the dosing of the first patient.

Hopefully we will also get news about FDA goodies coming with the Phase 1aMk2 study and later with the Phase 2 study.

Also worth noting that the IP protection covers diseases where FAP is up regulated other than cancer - inflammation, wounds, fibrosis - anywhere where tissue remodelling (tissue growth) is taking place.

Also worth noting that it follows from this that growing children have up regulated FAP, which is why low FAP levels in 'normal' tissue is usually qualified with "adult". When not qualified, it is implicit or understood that that is the case.

There are a few caveats about that FAP concentration data.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581228/

"Patient numbers were not sufficient to compare the SUVs of primary tumors versus metastases for individual cancers. ... Subsequently, we analyzed primary and metastatic lesions of individual tumor entities in a pooled fashion."

For the concentrations graph (Figure 2 in the paper), note the large distribution spread bars on most as well as the low sample numbers (n) for most.

"FIGURE 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581228/figure/fig2/

"Average SUVmax of 68Ga-FAPI PET/CT in various tumor entities. Low, intermediate, and high uptake was defined by cutoff at SUVs 6 and 12. By comparison, average background (blood pool) was found to have SUV 1.4. Ca = cancer; CCC = cholangiocellular carcinoma; CUP = carcinoma of unknown primary; HCC = hepatocellular carcinoma; NET = neuroendocrine tumor."

Also, STS is not a single cancer but has, if memory serves, 100+ subtypes and Alan has said that the response to AVA6000 varies greatly between then - due to different FAP concentrations or something else he didn't specify.

TMAC uses both Avacta (Affimers) and Tufts (pre|CISION) IP.

Eli Lilly have deep pockets for the CanSEEK milestone payments and royalties. I can't see them scraping the projects so, barring Eli Lilly going bankrupt (far, far less likely than POINT had of going bust), the milestone payments and royalties will get paid, giving Avacta security of income.

Https://www.pointbiopharma.com/our-products/pipeline